ArticleESC heart failure2024
Outcome prediction by myocardial external efficiency from
Article in ESC heart failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Infiltrative and Inflammatory Cardiomyopathies: Using Imaging to Probe Mechanisms of Myocardial Dysfunction.Journal of cardiac failure · 2026Review
- Characteristics and clinical significance of myocardial work in cardiac light-chain amyloidosis: pressure-volume loop analysis based on cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance · 2026Article
- Transthyretin amyloid cardiomyopathy-new data regarding epidemiology, diagnosis, and treatment.ESC heart failure · 2026Article
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Automatic volumetric estimates of the left and right atrium using dynamic PET.EJNMMI research · 2025Article
- Arrhythmia-Induced Cardiomyopathy in Atrial Fibrillation: Pathogenesis, Diagnosis, and Treatment.Life (Basel, Switzerland) · 2025Review
- Imaging of metabolic dysfunction in genetic cardiomyopathies.The international journal of cardiovascular imaging · 2025Review
- Echocardiographic risk stratification in light chain and transthyretin amyloidosis: a meta-analysis.European heart journal open · 2025Article
- 2024 update in heart failure.ESC heart failure · 2025Review
- 2025 Update Consensus ofActa Cardiologica Sinica · 2025Article
- Outcome prediction by myocardial external efficiency fromESC heart failure · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
Abstract
aimsThis study aimed to study the prognostic value of myocardial oxygen consumption (MVO METHODS AND
resultsForty-eight CA patients, both transthyretin (ATTR) and immunoglobulin light chain (AL) amyloidosis, and 20 controls were included. All subjects were examined with
conclusionsReduced MEE was associated with shorter survival in CA patients, but FSV/LVM was the strongest survival predictor and the only independently prognostic
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.